vs
Side-by-side financial comparison of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and TRINITY BIOTECH PLC (TRIB). Click either name above to swap in a different company.
LIFECORE BIOMEDICAL, INC. \DE\ is the larger business by last-quarter revenue ($31.1M vs $30.5M, roughly 1.0× TRINITY BIOTECH PLC). LIFECORE BIOMEDICAL, INC. \DE\ runs the higher net margin — -32.1% vs -33.0%, a 0.9% gap on every dollar of revenue. LIFECORE BIOMEDICAL, INC. \DE\ produced more free cash flow last quarter ($25.0K vs $-4.1M).
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
Trinity Biotech PLC develops, manufactures and markets diagnostic test kits and systems for clinical laboratories and point-of-care settings. Its product portfolio covers diabetes management, infectious diseases, cardiac health, autoimmune disorders and coagulation, with core markets across North America, Europe and emerging economies.
LFCR vs TRIB — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $31.1M | $30.5M |
| Net Profit | $-10.0M | $-10.1M |
| Gross Margin | 25.0% | 36.8% |
| Operating Margin | -9.9% | -23.2% |
| Net Margin | -32.1% | -33.0% |
| Revenue YoY | -4.5% | — |
| Net Profit YoY | -52.0% | — |
| EPS (diluted) | $-0.29 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $31.1M | — | ||
| Q1 25 | $35.2M | — | ||
| Q4 24 | $32.6M | — | ||
| Q3 24 | $24.7M | — | ||
| Q2 24 | — | $30.5M | ||
| Q1 24 | $35.7M | — | ||
| Q4 23 | $30.1M | — | ||
| Q3 23 | $24.5M | — |
| Q3 25 | $-10.0M | — | ||
| Q1 25 | $-14.8M | — | ||
| Q4 24 | $-6.6M | — | ||
| Q3 24 | $-16.2M | — | ||
| Q2 24 | — | $-10.1M | ||
| Q1 24 | $15.6M | — | ||
| Q4 23 | $14.2M | — | ||
| Q3 23 | $-10.8M | — |
| Q3 25 | 25.0% | — | ||
| Q1 25 | 28.0% | — | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 21.8% | — | ||
| Q2 24 | — | 36.8% | ||
| Q1 24 | 33.3% | — | ||
| Q4 23 | 33.0% | — | ||
| Q3 23 | 11.1% | — |
| Q3 25 | -9.9% | — | ||
| Q1 25 | -25.7% | — | ||
| Q4 24 | -6.0% | — | ||
| Q3 24 | -46.9% | — | ||
| Q2 24 | — | -23.2% | ||
| Q1 24 | -2.5% | — | ||
| Q4 23 | -4.9% | — | ||
| Q3 23 | -35.1% | — |
| Q3 25 | -32.1% | — | ||
| Q1 25 | -42.0% | — | ||
| Q4 24 | -20.2% | — | ||
| Q3 24 | -65.7% | — | ||
| Q2 24 | — | -33.0% | ||
| Q1 24 | 43.8% | — | ||
| Q4 23 | 47.2% | — | ||
| Q3 23 | -43.9% | — |
| Q3 25 | $-0.29 | — | ||
| Q1 25 | $-0.47 | — | ||
| Q4 24 | $-0.25 | — | ||
| Q3 24 | $-0.53 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $0.42 | — | ||
| Q4 23 | $0.39 | — | ||
| Q3 23 | $-0.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.9M | $5.3M |
| Total DebtLower is stronger | $136.0M | — |
| Stockholders' EquityBook value | $-10.5M | $-29.4M |
| Total Assets | $235.2M | $94.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $18.9M | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $9.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q3 25 | $136.0M | — | ||
| Q1 25 | $124.9M | — | ||
| Q4 24 | $111.3M | — | ||
| Q3 24 | $106.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $97.1M | — | ||
| Q4 23 | $92.9M | — | ||
| Q3 23 | $88.8M | — |
| Q3 25 | $-10.5M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $15.4M | — | ||
| Q3 24 | $-3.9M | — | ||
| Q2 24 | — | $-29.4M | ||
| Q1 24 | $17.7M | — | ||
| Q4 23 | $1.4M | — | ||
| Q3 23 | $-13.6M | — |
| Q3 25 | $235.2M | — | ||
| Q1 25 | $237.7M | — | ||
| Q4 24 | $255.4M | — | ||
| Q3 24 | $246.8M | — | ||
| Q2 24 | — | $94.4M | ||
| Q1 24 | $246.2M | — | ||
| Q4 23 | $245.8M | — | ||
| Q3 23 | $245.6M | — |
| Q3 25 | — | — | ||
| Q1 25 | 56.05× | — | ||
| Q4 24 | 7.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.49× | — | ||
| Q4 23 | 65.35× | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-3.9M |
| Free Cash FlowOCF − Capex | $25.0K | $-4.1M |
| FCF MarginFCF / Revenue | 0.1% | -13.3% |
| Capex IntensityCapex / Revenue | 5.6% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-16.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $1.8M | — | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $-6.1M | — | ||
| Q3 24 | $-613.0K | — | ||
| Q2 24 | — | $-3.9M | ||
| Q1 24 | $-1.4M | — | ||
| Q4 23 | $1.3M | — | ||
| Q3 23 | $-8.3M | — |
| Q3 25 | $25.0K | — | ||
| Q1 25 | $-4.3M | — | ||
| Q4 24 | $-8.6M | — | ||
| Q3 24 | $-4.0M | — | ||
| Q2 24 | — | $-4.1M | ||
| Q1 24 | $-7.8M | — | ||
| Q4 23 | $-3.0M | — | ||
| Q3 23 | $-13.4M | — |
| Q3 25 | 0.1% | — | ||
| Q1 25 | -12.1% | — | ||
| Q4 24 | -26.3% | — | ||
| Q3 24 | -16.3% | — | ||
| Q2 24 | — | -13.3% | ||
| Q1 24 | -21.8% | — | ||
| Q4 23 | -9.9% | — | ||
| Q3 23 | -54.6% | — |
| Q3 25 | 5.6% | — | ||
| Q1 25 | 15.5% | — | ||
| Q4 24 | 7.5% | — | ||
| Q3 24 | 13.9% | — | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | 17.8% | — | ||
| Q4 23 | 14.1% | — | ||
| Q3 23 | 20.6% | — |
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.09× | — | ||
| Q4 23 | 0.09× | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
TRIB
Segment breakdown not available.
